Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies

PharmacoEconomics

Volumn 20, Issue 14, 2002, Pages 963-977

  Levy, Emile ^a   Levy, Pierre ^a  

^a UNIVERSITÉ PARIS DAUPHINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; HYDRALAZINE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LOSARTAN; METOPROLOL; MILRINONE; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL;

CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HEART EJECTION FRACTION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT;

EID: 0036439859     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220140-00002     Document Type: Review

References (109)

1. Delahaye F, de Gevigney G, Gaillard S. et al. Epidémiologie et impact économique de l'insuffisance cardiaque en France. Arch Mal Coeur Vaiss 1998; 91: 1307-14
2. Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. Pharmacoeconomics 1995; 7 (2): 119-27
3. Launois R, Launois B, Reboul-Marty J, et al. Le coût de la sévérité de la maladie: Le cas de l'insuffisance cardiaque. Journal d'Economie Médicale 1990; 8 (7-8): 395-412
4. McMurray JJ, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med 1993; 6: 99-110
5. Davey PG, Clarkson PB, Mc Mahon A, et al. Costs associated with symptomatic systolic heart failure. Pharmacoeconomics 1999; 16 (4): 399-407
6. Levy P, Dubois-Randé JL, Cohen-Solal A, et al. L'apport du carvedilol dans le traitement de l'insuffisance cardiaque: Une étude coût-efficacité appliqué au cas de la France. Arch Mal Coeur Vaiss 2001; 94 (2): 166-70
7. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9 (3): 188-97
8. Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998; 19 Suppl. P: 2-4
9. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias. Prog Cardiovasc Dis 1995; 37 (5): 307-46
10. Galbraith A, Wright-Smith G. Heart failure. New treatment options. Aust Fam Physician 1996; 25 (7): 1035, 1038-43
11. Parmley WW. Cost-effective management of heart failure. Clin Cardiol 1996; 19 (3): 240-2
12. Willens HJ, Chakko S, Simmons J, et al. Cost-effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure. Chest 1996; 109 (5): 1359-69
13. Pepine CJ. Adjunctive therapies for acute myocardial infarction became a little clearer in 1993. J Myocardial Ischemia 1994; 6 (1): 6-7
14. Cleland JG. ACE inhibitors: Current understanding and future directions. Br Heart J 1994; 72 (3 Suppl.): S1
15. Desnos M. Heart failure management: A challenge for the 3rd millennium [editorial]. Arch Mal Coeur Vaiss 1998; 91 (11): 1303
16. Rich MW. Multidisciplinary interventions for the management of heart failure: Where do we stand? [editorial; comment]. Am Heart J 1999; 138 (4 Pt 1): 599-601
17. Ward RE, Gheorghiade M, Young JB, et al. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995; 26 (1): 93-101
18. Cleland JG. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998; 19 Suppl. P: 32-9
19. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: The case of heart failure. Arch Intern Med 1999; 159 (15): 1690-700
20. Heaton AH, Bryant J, Berman BN, et al. A pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure. Am J Manag Care 1996; 2: 1428-34
21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709-17
22. Leizorovicz A, Cucherat M. Economic evaluation of treatments of cardiac insufficiency. Arch Mal Coeur Vaiss 1994; 87 (2): 39-44
23. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: New strategies justified by recent clinical trials. Int J Cardiol 1994; 43: 151-63
24. Davie AP, McMurray JJ. ACE inhibitors and health-care economics. Coron Artery Dis 1995; 6 (4): 315-9
25. Gerbrandt KR, Yedinak KC. Formulary management of ACE inhibitors. Pharmacoeconomics 1996; 10 (6): 594-613
26. Giles T. The cost-effective way forward for the management of the patient with heart failure. Cardiology 1996; 87 Suppl. 1: 33-9
27. Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 1997; 10 (10 Pt 2): S272-9
28. Boyko Jr WL, Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: ACE inhibitors in the management of congestive heart failure: Comparative economic data. Am Heart J 1999; 137 (5): S115-9
29. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316 (23): 1429-35
30. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314 (24): 1547-52
31. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293-302
32. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 (10): 685-91
33. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327 (10): 669-77
34. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342 (8875): 821-8
35. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333 (25): 1670-6
36. Hart W, Rhodes G, McMurray J. The cost-effectiveness of enalapril in the treatment of chronic heart failure. Br J Med Econ 1993; 6: 91-8
37. van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in The Netherlands: A pharmacoeconomic model. Pharmacoeconomics 1993; 3 (5): 387-97
38. Paul SD, Kuntz KM, Eagle KA, et al. Cost and effectiveness of Angiotensin Converting Enzyme Inhibitor in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143-9
39. Glick H, Cook J, Kinosian B, et al. Costs and effect of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the Studies Of Left Ventriacular Dysfunction (SOLVD) treatment trial. J Card Fail 1995; (1): 371-80
40. Butler JR, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med 1996; 26 (1): 89-95
41. Scott WG, Scott HM. Heart failure: A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction. Pharmacoeconomics 1996; 9 (2): 156-67
42. Le Pen C, Levy E, Bonte J. Cost-effectiveness analysis of captopril treatment after myocardial infarction. Arch Mal Coeur Vaiss 1994; 87 (6): 775-81
43. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy. J Am Coll Cardiol 1995; 26 (4): 914-9
44. Michel BC, Al MJ, Remme WJ, et al. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands [see comments]. Eur Heart J 1996; 17 (5): 731-40
45. Hummel S, Piercy J, Wright R, et al. An economic analysis of the Survival And Ventricular Enlargment (SAVE) study: Application to United Kingdom. Pharmacoeconomics 1997; 12: 183-91
46. Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy [published erratum appears in Pharmacoeconomics 1997 Dec; 12 (6): 706]. Pharmacoeconomics 1997; 12 (2 Pt 2): 256-66
47. Martinez C, Ball SG. Cost-effectiveness of ramipril for patients with clinical evidence of heart failure after acute myocardial infarction. Br J Clin Pract 1995; Suppl. 7/8: S26-32
48. Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 1998; 14 (6): 653-69
49. Le Pen C, Liliu H, Keller T, et al. The economics of TRACE: A cost-effectiveness analysis of trandolapril in post-infarction patients with left ventricular dysfunction. Pharmacoeconomics 1998; 14 (1): 49-58
50. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6
51. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost-effectiveness league tables. BMJ 1993; 306: 570-2
52. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. Circulation 1994; 90 (4): 1765-73
53. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353 (9146): 9-13
54. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334 (21): 1349-55
55. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001-7
56. Dargie H. CAPRICORN: A multinational, randomized, double-blind study on the effects of carvedilol on mortalilty and morbidity in patients with left ventricular dysfunction after myocardial infarction. American College of Cardiology 50th Scientific Session: 2001 Mar 18-21; Orlando (FL)
57. Packer M. COPERNICUS: A multicenter, randomized, double-blind placebo-controlled study to determine the effect of carvedilol on mortality in patients with severe chronic heart failure. American College of Cardiology 50th Scientific Session; 2001 Mar 18-21; Orlando (FL)
58. Levy P, Lechat P, Leizorovicz A, et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: An analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998; 12(3): 301-5
59. Schadlich PK, Paschen B, Brecht JG. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. Pharmacoeconomics 1998; 13 (1 Pt 2): 147-55
60. Malek M, Cunningham-Davis J, Malek L, et al. A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Int J Clin Pract 1999; 53 (1): 19-23
61. Varney S. A cost-effectiveness analysis of bisoprolol for heart failure. Eur J Heart Fail 2001; 3: 365-71
62. Levy P, Mérot JL, Lechat P, et al. Bisoprolol dans l'insuffisance cardiaque: Efficacité et coûts dans le cadre français selon CIBIS II. Therapie 2001; 56: 421-5
63. Reduced costs with bisoprolol treatment for heart failure: An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS II). CIBIS II Investigators and Health Economic Group. Eur Heart J 2001; 22: 1021-31
64. Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999; 83 (6): 890-6
65. Fowler M, Vera-Llonch M, Oster G, et al., Influence of carvedilol on hospitalizations in heart failure: Incidence, resource utilization and costs. J Am Coll Cardiol 2001; 37: 1692-9
66. Eichorn EJ. Experience with beta-blockers in heart failure mortality trials. Clin Cardiol 1999; 22 Suppl. 5: V21-9
67. Gregory D, Udelson J, Konstam H. Economic impact of beta blockade in heart failure. Am J Med 2001; 110 Suppl. 7A: 74-80
68. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure [see comments]. Arch Intern Med 1994; 154 (10): 1143-9
69. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747-52
70. Dasbach EJ, Rich MW, Segal R, et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 1999; 91 (3): 189-94
71. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial, the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582-7
72. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335 (15): 1107-14
73. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96 (3): 856-63
74. Lombardi WL, Litwin SE. Angiotensin-converting enzyme inhibitors: Congestive heart failure and beyond. Coron Artery Dis 1999; 10 (6): 361-8
75. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: A cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996; 132 (4): 805-8
76. Cuffe MS, Califf RM, Adams KF, et al. Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J 2000; 139 (1 Pt 1): 15-22
77. Thackray S, Witte K, Clark AL, et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000; 2 (2): 209-12
78. Wood JM, Close P. Renin inhibitors: Cardiovascular drugs of the future? Cardiovasc Drugs Ther 1996; 10 (3): 309-12
79. Klein H, Auricchio A, Reek S. et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83 (5B): D91-7
80. Cannom DS. Other primary prevention trials-what is clinically and economically necessary? J Interv Card Electrophysiol 2000; 4 Suppl. 1: 109-15
81. Leidy NK, Rentz AM, Zyczynski TM. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure: A review of recent randomised controlled trials. Pharmacoeconomics 1999; 15 (1): 19-46
82. Berry C, McMurray JJ. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 1999; 16 (3): 247-71
83. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient. Am J Cardiol 1997; 80 (8B): H45-52
84. Lee AJ. The role of financial incentives in shaping clinical practice patterns and practice efficiency. Am J Cardiol 1997; 80 (8B): H28-32
85. Goldberg RJ, Meyer TE. Advances and stagnations in heart failure [editorial comment]. Arch Intern Med 1997; 157 (1): 17-9
86. Auerbach AD, Hamel MB, Davis RB, et al. Resource use and survival of patients hospitalized with congestive heart failure: Differences in care by specialty of the attending physician. Support Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments [see comments]. Ann Intern Med 2000; 132 (3): 191-200
87. McMurray JJ. Failure to practice evidence-based medicine: Why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19 Suppl. L: L15-21
88. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age. Am J Cardiol 1997; 79 (5): 581-6
89. Boccuzzi SJ. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: A pharmaceutical industry perspective. Am Heart J 1999; 137 (5): S120-2
90. Monane M, Bohn RL, Gurwitz JH, et al. Noncompliance with congestive heart failure therapy in the elderly [see comments]. Arch Intern Med 1994; 154 (4): 433-7
91. Andersson F, Cline C, Ryden-Bergsten T, et al. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing. Pharmacoeconomics 1999; 15 (6): 535-50
92. Bradford D, Chen J, Krumholz M. Under-utilization of beta-blockers after acute myocardial infarction, pharmacoeconomic implications. Pharmacoeconomics 1999; 15 (3): 257-68
93. McMurray JV, McDonagh TA, Davie AP, et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19 (6): 842-6
94. Afzal A, Brawner CA, Keteyian SJ. Exercise training in heart failure. Prog Cardiovasc Dis 1998; 41 (3): 175-90
95. Kornowski R, Zeeli D, Averbuch M, et al. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure. Am Heart J 1995; 129 (4): 762-6
96. Paul S. Impact of a nurse-managed heart failure clinic: A pilot study. Am J Crit Care 2000; 9 (2): 140-6
97. Stewart S. An economic analysis of specialist nurse management of heart failure: can we afford not to implement it? [abstract]. Eur Heart J 2001; 22: 626
98. Bouhour JB. Education of patients with heart failure. Arch Mal Coeur Vaiss 1998; 91 (11): 1407-10
99. Rich MW, Vinson JM, Sperry JC, et al. Prevention of readmission in elderly patients with congestive heart failure: Results of a prospective, randomized pilot study. J Gen Intern Med 1993; 8 (11): 585-90
100. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997; 30 (3): 725-32
101. Cline CM, Israelsson BY, Willenheimer RB, et al. Cost effective management programme for heart failure reduces hospitalisation [see comments]. Heart 1998; 80 (5): 442-6
102. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190-5
103. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001; 161: 2223-8
104. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. Am Heart J 1998; 135 (6 Pt 2 Su): S285-92
105. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001; 110 (5): 378-84
106. Tunstall-Pedoe H. Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-Year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353 (9164): 1547-57
107. Cleland JG. Improving patient outcomes in heart failure: Evidence and barriers. Heart 2000; 84 Suppl. 1: i8-10, i50
108. Coats AJ. Beta-blockers: Again, a lesson to us all, especially the research funding community [editorial]. Int J Cardiol 2000; 73 (2): 103-4
109. Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the first study: Design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. Control Clin Trials 1996; 17 (4): 304-15